PDF(Pubmed)
Abstract：
Achieving long-term disease control using therapeutic immunomodulation is a long-standing concept with a strong tradition in blood malignancies. Besides allogeneic hematopoietic stem cell transplantation that continues to provide potentially curative treatment for otherwise challenging diagnoses, recent years have seen impressive progress in immunotherapies for leukemias and lymphomas with immune checkpoint blockade, bispecific monoclonal antibodies, and CAR T cell therapies. Despite their success, non-response, relapse, and immune toxicities remain frequent, thus prioritizing the elucidation of the underlying mechanisms and identifying predictive biomarkers. The increasing availability of single-cell genomic tools now provides a system\'s immunology view to resolve the molecular and cellular mechanisms of immunotherapies at unprecedented resolution. Here, we review recent studies that leverage these technological advancements for tracking immune responses, the emergence of immune resistance, and toxicities. As single-cell immune monitoring tools evolve and become more accessible, we expect their wide adoption for routine clinical applications to catalyze more precise therapeutic steering of personal immune responses.
摘要：
使用治疗性免疫调节实现长期疾病控制是一个长期存在的概念，在血液恶性肿瘤中具有悠久的传统。除了异基因造血干细胞移植，继续为其他具有挑战性的诊断提供潜在的治愈性治疗，近年来，在免疫检查点阻断的白血病和淋巴瘤的免疫治疗方面取得了令人印象深刻的进展，双特异性单克隆抗体，和CART细胞疗法。尽管他们取得了成功,无反应,复发,免疫毒性仍然很常见，因此优先阐明潜在机制并确定预测性生物标志物.现在，越来越多的单细胞基因组工具提供了一个系统的免疫学观点，以前所未有的分辨率解决免疫疗法的分子和细胞机制。这里,我们回顾了利用这些技术进步来跟踪免疫反应的最新研究，免疫抗性的出现，和毒性。随着单细胞免疫监测工具的发展和变得更容易获得，我们期望它们广泛用于常规临床应用，以催化更精确的治疗指导个人免疫反应。
